Abstracts from the Mid-Atlantic Section of the AUA 2020

© The Canadian Journal of Urology TM : International Supplement, October 2020 Prolaris Score Prediction of Adverse Pathology Following Radical Prostatectomy: A Risk Stratified Analysis S.Azari; J. Kashkoush; M. Su; B. Croll; J. Feliciano; C. Georges; J. Johannes;A. Baccala Lehigh Valley Health Network, Allentown, PA, USA Introduction: The association between Cell Cycle Progression (CCP) score, or the Prolaris score, and adverse pathology after radical prostatectomy has not been fully evaluated. Our initial findings demonstrating that CCP score was positively associatedwith adverse pathology were presented at the 2019MAAUA. We present here our findings of the relationship between CCP score and adverse pathology after risk stratifying patients based on their Cancer of the Prostate RiskAssessment (CAPRA) scores. Materials & Methods: A retrospective review of patients who had received CCP testing and underwent radical prostatectomy fromNovember 1, 2015 to December 31, 2018was performed.Adverse pathologywas defined as a post-operative Gleason score of 8 or greater, positive lymph nodes, extracapsular extension (stage pT3a), or seminal vesicle invasion (stage pT3b). CAPRA scores were then calculated for each patient. To assess the relationship between CCP score and adverse pathology, a logistic regression analysis was performed while adjusting for CAPRA score. Results: Of the 173 patients that met inclusion criteria, 53 demonstrated adverse pathology (Table 1). Patients from most American Urologic Association risk categories were represented. CCPwas positively associatedwith adverse pathology, with an odds ratio per 1 CCP units of 3.246 (p < 0.001). After adjusting for CAPRA score, CCP remained positively associated with adverse pathology, with an odds ratio per 1 CCP units of 2.920 (p < 0.001). The distribution of CAPRA scores is shown in Figure 1. Conclusions: After adjusting for CAPRA score, CCP scores are still positively associated with adverse pathology after radical prostatectomy. Poster Session 6: Urologic Oncologic Disease MP6-15 46